NCT01021553View on ClinicalTrials.gov

A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

December 23, 2009

Primary Completion Date

May 5, 2011

Study Completion Date

May 5, 2011

Conditions
Premature Ejaculation
Interventions
DRUG

GSK557296

50 mg GSK557296

DRUG

GSK557296

150 mg GSK557296

DRUG

placebo

placebo

Trial Locations (8)

10016

GSK Investigational Site, New York

19004

GSK Investigational Site, Bala-Cynwyd

19104

GSK Investigational Site, Philadelphia

46825

GSK Investigational Site, Fort Wayne

92120

GSK Investigational Site, San Diego

95128

GSK Investigational Site, San Jose

1081 HV

GSK Investigational Site, Amsterdam

3584 CJ

GSK Investigational Site, Utrecht

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01021553 - A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation | Biotech Hunter | Biotech Hunter